Screening of prognostic risk microRNAs for acute myeloid leukemia

References

• Fröhling S, Scholl C, Gilliland DG, et al. Genetics of myeloid malignancies: pathogenetic and clinical implications. J Clin Oncol. 2005;23(26):6285–6295. doi: 10.1200/JCO.2005.05.010
   PubMed Web of Science ®Google Scholar
• Murati A, Brecqueville M, Devillier R, et al. Myeloid malignancies: mutations, models and management. BMC Cancer. 2012;12(1):304. doi: 10.1186/1471-2407-12-304
   PubMedGoogle Scholar
• Toyota M, Kopecky KJ, Toyota M-O, et al. Methylation profiling in acute myeloid leukemia. Blood. 2001;97(9):2823–2829. doi: 10.1182/blood.V97.9.2823
   PubMed Web of Science ®Google Scholar
• Kroeger H, Jelinek J, Estécio MR, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008;112(4):1366–1373. doi: 10.1182/blood-2007-11-126227
   PubMed Web of Science ®Google Scholar
• Bullinger L, Ehrich M, Döhner K, et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood. 2010;115(3):636–642. doi: 10.1182/blood-2009-03-211003
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010;17(1):13–27. doi: 10.1016/j.ccr.2009.11.020
   PubMed Web of Science ®Google Scholar
• Guo H, Ingolia NT, Weissman JS, et al. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835–840. doi: 10.1038/nature09267
   PubMed Web of Science ®Google Scholar
• Vasudevan S. Posttranscriptional upregulation by microRNAs. WIRES RNA. 2012;3(3):311–330. doi: 10.1002/wrna.121
   Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–866. doi: 10.1038/nrc1997
   PubMed Web of Science ®Google Scholar
• Mi S, Lu J, Sun M, et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A. 2007;104(50):19971–19976. doi: 10.1073/pnas.0709313104
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M, Sun SM, Dijkstra MK, et al. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood. 2008;111(10):5078–5085. doi: 10.1182/blood-2008-01-133355
   PubMed Web of Science ®Google Scholar
• Dixon-McIver A, East P, Mein CA, et al. Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PloS One. 2008;3(5):e2141. doi: 10.1371/journal.pone.0002141
   PubMed Web of Science ®Google Scholar
• Garzon R, Volinia S, Liu C-G, et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008;111(6):3183–3189. doi: 10.1182/blood-2007-07-098749
   PubMed Web of Science ®Google Scholar
• Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1919–1928. doi: 10.1056/NEJMoa074256
   PubMed Web of Science ®Google Scholar
• Bolstad B. PreprocessCore: a collection of pre-processing functions. R package version. 2013;1(0).
   Google Scholar
• Therneau TM. Modeling survival data: extending the Cox model. New York: Springer; 2000.
   Google Scholar
• Dweep H, Sticht C, Pandey P, et al. Mirwalk – database: prediction of possible miRNA binding sites by ‘walking’ the genes of three genomes. J Biomed Inform. 2011;44(5):839–847. doi: 10.1016/j.jbi.2011.05.002
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi: 10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Franceschini A, Szklarczyk D, Frankild S, et al. String v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2012;41(D1):D808–D815. doi: 10.1093/nar/gks1094
   PubMed Web of Science ®Google Scholar
• DennisJrG, Sherman BT, Hosack DA, et al. David: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):P3. doi: 10.1186/gb-2003-4-5-p3
   PubMed Web of Science ®Google Scholar
• San José-Enériz E, Román-Gómez J, Jiménez-Velasco A, et al. Microrna expression profiling in imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations. Mol Cancer. 2009;8(1):69–72. doi: 10.1186/1476-4598-8-69
   PubMedGoogle Scholar
• Scheepers ER, Kampen KR, de Bont ES. Inhibition of EGFR activity reduces AML cell survival via inhibition of downstream Akt and Erk signaling pathways. Cancer Res. 2013;73(8 Supplement):2772. doi: 10.1158/1538-7445.AM2013-2772
   Google Scholar
• Boehrer S, Galluzzi L, Lainey E, et al. Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia. Cell Cycle. 2011;10(18):3168–3175. doi: 10.4161/cc.10.18.16599
   PubMed Web of Science ®Google Scholar
• Gilmore TD, Kalaitzidis D, Liang M-C, et al. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene. 2004;23(13):2275–2286. doi: 10.1038/sj.onc.1207410
   PubMed Web of Science ®Google Scholar
• Raymond A, Liu B, Liang H, et al. A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy. Oncotarget. 2014;5(24):12675. doi: 10.18632/oncotarget.2564
   PubMedGoogle Scholar
• Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23(6):1019–1028. doi: 10.1038/leu.2008.397
   PubMed Web of Science ®Google Scholar
• Marks PA, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1(3):194–202. doi: 10.1038/35106079
   PubMed Web of Science ®Google Scholar
• Wada T, Kikuchi J, Nishimura N, et al. Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J Biol Chem. 2009;284(44):30673–30683. doi: 10.1074/jbc.M109.042242
   PubMed Web of Science ®Google Scholar
• Lepore I, Dell’Aversana C, Pilyugin M, et al. Hdac inhibitors repress BARD1 isoform expression in acute myeloid leukemia cells via activation of miR-19a and/or b. PloS One. 2013;8(12):e83018. doi: 10.1371/journal.pone.0083018
   PubMed Web of Science ®Google Scholar
• Schotte D, De Menezes RX, Moqadam FA, et al. Micrornas characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia. Haematologica. 2011;96:703–711. haematol. 2010.026138. doi: 10.3324/haematol.2010.026138
   PubMed Web of Science ®Google Scholar
• Lamb R, Sneddon S, Hulit J, et al. Mitochondria ‘fuel’ breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. Cell Cycle. 2012;11(23):4390–4401. doi: 10.4161/cc.22777
   PubMed Web of Science ®Google Scholar
• Tsai S-C, Valkov N, Yang W-M, et al. Histone deacetylase interacts directly with DNA topoisomerase II. Nat Genet. 2000;26(3):349–353. doi: 10.1038/81671
   PubMed Web of Science ®Google Scholar
• Beck J, Niethammer D, Gekeler V. Mdr1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias. Leukemia. 1996;10:S39–S45.
   PubMed Web of Science ®Google Scholar
• Juan AH, Kumar RM, Marx JG, et al. Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol Cell. 2009;36(1):61–74. doi: 10.1016/j.molcel.2009.08.008
   PubMed Web of Science ®Google Scholar
• Fiskus W, Wang Y, Sreekumar A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood. 2009;114(13):2733–2743. doi: 10.1182/blood-2009-03-213496
   PubMed Web of Science ®Google Scholar
• Gentry AC, Juul S, Veigaard C, et al. The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I. Nucleic Acids Res. 2010;39:1014–1022. gkq822. doi: 10.1093/nar/gkq822
   PubMed Web of Science ®Google Scholar
• Potenza L, Sinigaglia B, Luppi M, et al. A t(11;20)(p15;q11) may identify a subset of nontherapy-related acute myelocytic leukemia. Cancer Genet Cytogenet. 2004;149(2):164–168. doi: 10.1016/j.cancergencyto.2003.07.002
   PubMedGoogle Scholar
• Ramsingh G, Koboldt DC, Trissal M, et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood. 2010;116(24):5316–5326. doi: 10.1182/blood-2010-05-285395
   PubMed Web of Science ®Google Scholar
• Cammarata G, Augugliaro L, Salemi D, et al. Differential expression of specific microRNA and their targets in acute myeloid leukemia. Am J Hematol. 2010;85(5):331–339.
   PubMed Web of Science ®Google Scholar